Recognizing the pivotal role of glycolytic metabolism in sepsis-induced organ injury, the therapeutic administration of 2-deoxy-D-glucose (2-DG) to inhibit glycolysis has been shown to upregulate SIRT3 and p-AMPK expression, thereby significantly ameliorating sepsis-induced renal injury. The gene discussed is SIRT3; the disease is Sepsis.